Junmaikang (adalimumab biosimilar) / Shanghai Junshi Biosci, Mabwell (Shanghai) Biosci, Binnopharm - LARVOL DELTA

Mabwell…announced that its Adalimumab Injection 9MW0113 (Marketed as JUNMAIKANG in China) has been granted marketing authorization by the Indonesian Food and Drug Authority… (PRNewswire) - "Co-developed by Mabwell and Junshi Biosciences, 9MW0113 has become the first Adalimumab biosimilar independently developed in China to receive marketing approval from BPOM. To date, Mabwell has signed formal cooperation agreements for 9MW0113 in more than ten countries and has submitted registration applications in multiple countries, including Jordan and Peru."

Approval • Filing • Ankylosing Spondylitis • Crohn's disease • Hidradenitis Suppurativa • Idiopathic Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Ulcerative Colitis • Uveitis

Mabwell Bioscience Partners with Binnopharm Group to Market 9MW0113, 9MW0321 and 9MW0311 in Russia and Eurasian Economic Union Countries (PRNewswire) - "Mabwell Bioscience...announced the company has entered into an licensing agreement with the Russian pharmaceutical company Binnopharm Group, for 9MW0113, 9MW0321 and 9MW0311, its Adalimumab and Denosumab biosimilars, under which Binnopharm Group will have exclusive rights to develop, register, manufacture and market the drugs with a status of local product in Russia and Eurasian Economic Union countries."

Licensing / partnership • Immunology • Oncology • Osteoporosis

Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection (GlobeNewswire) - "Shanghai Junshi Biosciences Co., Ltd...announced today that the supplemental application for additional indications of adalimumab injection (project code: UBP1211...) for the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children has been approved by the National Medical Products Administration ('NMPA')."

Non-US regulatory • Crohn's disease • Idiopathic Arthritis • Immunology • Inflammatory Bowel Disease • Psoriasis • Uveitis

Junshi Biosciences Announces Acceptance of Supplemental Application for Additional Indications of Adalimumab Injection (GlobeNewswire) - "Shanghai Junshi Biosciences Co., Ltd...announced today that the Company has received an Acceptance Notice issued by the National Medical Products Administration ('NMPA'). The supplemental application for additional indications of the company’s adalimumab injection (project code: UBP1211, trade name: Junmaikang), including the treatment of Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, plaque psoriasis in children and Crohn’s disease in children, has been accepted."

Non-US regulatory • Crohn's disease • Immunology • Inflammatory Bowel Disease